ClinicalTrials.Veeva

Menu

PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow

D

Danish Headache Center

Status

Completed

Conditions

Migraine Without Aura

Treatments

Drug: PACAP38

Study type

Interventional

Funder types

Other

Identifiers

NCT00380263
KA-20060087

Details and patient eligibility

About

To investigate headache score and accompanying symptoms during and after infusion of PACAP38 i migraine patients

Full description

To investigate headache score and accompanying symptoms during and after infusion of PACAP38

Changes in regional cerebral blood flow (rCBF) in the area supplied by middle cerebral artery (MCA), blood flow in MCA, diameter of the superficial temporal artery (STA) and radial artery (RA)

Enrollment

12 patients

Sex

All

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Healthy migraine patient without aura
  • Aged 18-50
  • 50-100 kg
  • Fertile women must use safe contraceptives (IUD, oral contraceptives, surgical sterilisation and long lasting gestagen.

Exclusion criteria

  • Tension type headache more than five times/month
  • Other primary headaches
  • Daily medication except contraceptives
  • Drug taken within 4 times the halflife for the specific drug except contraceptives
  • Pregnant or lactating women
  • Exposure to radiation within the last year
  • Headache within the last 48 hours before start of trial
  • Hypertension
  • Hypotension
  • Respiratory or cardiac disease

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems